Long-term outcomes following bioresorbable vascular scaffolds

Kotaro Miyashita,Kai Ninomiya,Akihiro Tobe,Shinichiro Masuda,Nozomi Kotoku,Shigetaka Kageyama,Pruthvi C Revaiah,Tsung-Ying Tsai,Bo Wang,Scot Garg,Patrick W Serruys,Yoshinobu Onuma
DOI: https://doi.org/10.1080/14779072.2024.2375340
Abstract:Introduction: The higher scaffold thrombosis rates observed with the first-generation bioresorbable scaffolds (BRSs) compared to conventional drug-eluting stents were likely due in part to bioresorbable polymers having insufficient radial strength, necessitating larger strut profiles. Meta-analysis of the long-term outcomes from the first-generation Absorb bioresorbable vascular scaffold (BVS) showed that this period of excess risk ended at 3 years. Therefore, current attention has been focused on improving early outcomes by increasing the scaffold's tensile strength and reducing strut thickness. Areas covered: This review summaries the lessons learned from the first-generation BRS. It updates the long-term clinical outcomes of trials evaluating the ABSORB BVS and metallic alloy-based BRS. In addition, it reviews the next-generation BRSs manufactured in Asia. Expert opinion: Critical areas to improve the performance and safety of biodegradable scaffolds include further development in material science, surface modification, delivery systems, and long-term follow-up studies.
What problem does this paper attempt to address?